Afamelanotide for erythropoietic protoporphyria

J. G. Langendonk, M. Balwani, Karl Anderson, H. L. Bonkovsky, A. V. Anstey, D. M. Bissell, J. Bloomer, C. Edwards, N. J. Neumann, C. Parker, J. D. Phillips, H. W. Lim, I. Hamzavi, J. C. Deybach, R. Kauppinen, L. E. Rhodes, J. Frank, G. M. Murphy, F. P J Karstens, E. J G SijbrandsF. W M De Rooij, M. Lebwohl, H. Naik, C. R. Goding, J. H P Wilson, R. J. Desnick

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

BACKGROUND Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We evaluated the safety and efficacy of an α-melanocyte-stimulating hormone analogue, afamelanotide, to decrease pain and improve quality of life. METHODS We conducted two multicenter, randomized, double-blind, placebo-controlled trials of subcutaneous implants containing 16 mg of afamelanotide. Patients in the European Union (74 patients) and the United States (94 patients) were randomly assigned, in a 1:1 ratio, to receive a subcutaneous implant containing either afamelanotide or placebo every 60 days (a total of five implants in the European Union study and three in the U.S study). The type and duration of sun exposure, number and severity of phototoxic reactions, and adverse events were recorded over the respective 180-day and 270-day study periods. Quality of life was assessed with the use of validated questionnaires. A subgroup of U.S. patients underwent photoprovocation testing. The primary efficacy end point was the number of hours of direct exposure to sunlight without pain. RESULTS In the U.S. study, the duration of pain-free time after 6 months was longer in the afamelanotide group (median, 69.4 hours, vs. 40.8 hours in the placebo group; P = 0.04). In the European Union study, the duration of pain-free time after 9 months was also longer in the afamelanotide group than in the placebo group (median, 6.0 hours vs. 0.8 hours; P = 0.005), and the number of phototoxic reactions was lower in the the afamelanotide group (77 vs. 146, P = 0.04). In both trials, quality of life improved with afamelanotide therapy. Adverse events were mostly mild; serious adverse events were not thought to be related to the study drug. CONCLUSIONS Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.

Original languageEnglish (US)
Pages (from-to)48-59
Number of pages12
JournalNew England Journal of Medicine
Volume373
Issue number1
DOIs
StatePublished - Jul 2 2015

Fingerprint

Erythropoietic Protoporphyria
Quality of Life
European Union
Placebos
Pain
Solar System
Phototoxic Dermatitis
Melanocyte-Stimulating Hormones
afamelanotide
Sunlight
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Langendonk, J. G., Balwani, M., Anderson, K., Bonkovsky, H. L., Anstey, A. V., Bissell, D. M., ... Desnick, R. J. (2015). Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine, 373(1), 48-59. https://doi.org/10.1056/NEJMoa1411481

Afamelanotide for erythropoietic protoporphyria. / Langendonk, J. G.; Balwani, M.; Anderson, Karl; Bonkovsky, H. L.; Anstey, A. V.; Bissell, D. M.; Bloomer, J.; Edwards, C.; Neumann, N. J.; Parker, C.; Phillips, J. D.; Lim, H. W.; Hamzavi, I.; Deybach, J. C.; Kauppinen, R.; Rhodes, L. E.; Frank, J.; Murphy, G. M.; Karstens, F. P J; Sijbrands, E. J G; De Rooij, F. W M; Lebwohl, M.; Naik, H.; Goding, C. R.; Wilson, J. H P; Desnick, R. J.

In: New England Journal of Medicine, Vol. 373, No. 1, 02.07.2015, p. 48-59.

Research output: Contribution to journalArticle

Langendonk, JG, Balwani, M, Anderson, K, Bonkovsky, HL, Anstey, AV, Bissell, DM, Bloomer, J, Edwards, C, Neumann, NJ, Parker, C, Phillips, JD, Lim, HW, Hamzavi, I, Deybach, JC, Kauppinen, R, Rhodes, LE, Frank, J, Murphy, GM, Karstens, FPJ, Sijbrands, EJG, De Rooij, FWM, Lebwohl, M, Naik, H, Goding, CR, Wilson, JHP & Desnick, RJ 2015, 'Afamelanotide for erythropoietic protoporphyria', New England Journal of Medicine, vol. 373, no. 1, pp. 48-59. https://doi.org/10.1056/NEJMoa1411481
Langendonk JG, Balwani M, Anderson K, Bonkovsky HL, Anstey AV, Bissell DM et al. Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine. 2015 Jul 2;373(1):48-59. https://doi.org/10.1056/NEJMoa1411481
Langendonk, J. G. ; Balwani, M. ; Anderson, Karl ; Bonkovsky, H. L. ; Anstey, A. V. ; Bissell, D. M. ; Bloomer, J. ; Edwards, C. ; Neumann, N. J. ; Parker, C. ; Phillips, J. D. ; Lim, H. W. ; Hamzavi, I. ; Deybach, J. C. ; Kauppinen, R. ; Rhodes, L. E. ; Frank, J. ; Murphy, G. M. ; Karstens, F. P J ; Sijbrands, E. J G ; De Rooij, F. W M ; Lebwohl, M. ; Naik, H. ; Goding, C. R. ; Wilson, J. H P ; Desnick, R. J. / Afamelanotide for erythropoietic protoporphyria. In: New England Journal of Medicine. 2015 ; Vol. 373, No. 1. pp. 48-59.
@article{9be92634328748a8ac47c6d9caaed6f6,
title = "Afamelanotide for erythropoietic protoporphyria",
abstract = "BACKGROUND Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We evaluated the safety and efficacy of an α-melanocyte-stimulating hormone analogue, afamelanotide, to decrease pain and improve quality of life. METHODS We conducted two multicenter, randomized, double-blind, placebo-controlled trials of subcutaneous implants containing 16 mg of afamelanotide. Patients in the European Union (74 patients) and the United States (94 patients) were randomly assigned, in a 1:1 ratio, to receive a subcutaneous implant containing either afamelanotide or placebo every 60 days (a total of five implants in the European Union study and three in the U.S study). The type and duration of sun exposure, number and severity of phototoxic reactions, and adverse events were recorded over the respective 180-day and 270-day study periods. Quality of life was assessed with the use of validated questionnaires. A subgroup of U.S. patients underwent photoprovocation testing. The primary efficacy end point was the number of hours of direct exposure to sunlight without pain. RESULTS In the U.S. study, the duration of pain-free time after 6 months was longer in the afamelanotide group (median, 69.4 hours, vs. 40.8 hours in the placebo group; P = 0.04). In the European Union study, the duration of pain-free time after 9 months was also longer in the afamelanotide group than in the placebo group (median, 6.0 hours vs. 0.8 hours; P = 0.005), and the number of phototoxic reactions was lower in the the afamelanotide group (77 vs. 146, P = 0.04). In both trials, quality of life improved with afamelanotide therapy. Adverse events were mostly mild; serious adverse events were not thought to be related to the study drug. CONCLUSIONS Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.",
author = "Langendonk, {J. G.} and M. Balwani and Karl Anderson and Bonkovsky, {H. L.} and Anstey, {A. V.} and Bissell, {D. M.} and J. Bloomer and C. Edwards and Neumann, {N. J.} and C. Parker and Phillips, {J. D.} and Lim, {H. W.} and I. Hamzavi and Deybach, {J. C.} and R. Kauppinen and Rhodes, {L. E.} and J. Frank and Murphy, {G. M.} and Karstens, {F. P J} and Sijbrands, {E. J G} and {De Rooij}, {F. W M} and M. Lebwohl and H. Naik and Goding, {C. R.} and Wilson, {J. H P} and Desnick, {R. J.}",
year = "2015",
month = "7",
day = "2",
doi = "10.1056/NEJMoa1411481",
language = "English (US)",
volume = "373",
pages = "48--59",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "1",

}

TY - JOUR

T1 - Afamelanotide for erythropoietic protoporphyria

AU - Langendonk, J. G.

AU - Balwani, M.

AU - Anderson, Karl

AU - Bonkovsky, H. L.

AU - Anstey, A. V.

AU - Bissell, D. M.

AU - Bloomer, J.

AU - Edwards, C.

AU - Neumann, N. J.

AU - Parker, C.

AU - Phillips, J. D.

AU - Lim, H. W.

AU - Hamzavi, I.

AU - Deybach, J. C.

AU - Kauppinen, R.

AU - Rhodes, L. E.

AU - Frank, J.

AU - Murphy, G. M.

AU - Karstens, F. P J

AU - Sijbrands, E. J G

AU - De Rooij, F. W M

AU - Lebwohl, M.

AU - Naik, H.

AU - Goding, C. R.

AU - Wilson, J. H P

AU - Desnick, R. J.

PY - 2015/7/2

Y1 - 2015/7/2

N2 - BACKGROUND Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We evaluated the safety and efficacy of an α-melanocyte-stimulating hormone analogue, afamelanotide, to decrease pain and improve quality of life. METHODS We conducted two multicenter, randomized, double-blind, placebo-controlled trials of subcutaneous implants containing 16 mg of afamelanotide. Patients in the European Union (74 patients) and the United States (94 patients) were randomly assigned, in a 1:1 ratio, to receive a subcutaneous implant containing either afamelanotide or placebo every 60 days (a total of five implants in the European Union study and three in the U.S study). The type and duration of sun exposure, number and severity of phototoxic reactions, and adverse events were recorded over the respective 180-day and 270-day study periods. Quality of life was assessed with the use of validated questionnaires. A subgroup of U.S. patients underwent photoprovocation testing. The primary efficacy end point was the number of hours of direct exposure to sunlight without pain. RESULTS In the U.S. study, the duration of pain-free time after 6 months was longer in the afamelanotide group (median, 69.4 hours, vs. 40.8 hours in the placebo group; P = 0.04). In the European Union study, the duration of pain-free time after 9 months was also longer in the afamelanotide group than in the placebo group (median, 6.0 hours vs. 0.8 hours; P = 0.005), and the number of phototoxic reactions was lower in the the afamelanotide group (77 vs. 146, P = 0.04). In both trials, quality of life improved with afamelanotide therapy. Adverse events were mostly mild; serious adverse events were not thought to be related to the study drug. CONCLUSIONS Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.

AB - BACKGROUND Erythropoietic protoporphyria is a severe photodermatosis that is associated with acute phototoxicity. Patients with this condition have excruciating pain and a markedly reduced quality of life. We evaluated the safety and efficacy of an α-melanocyte-stimulating hormone analogue, afamelanotide, to decrease pain and improve quality of life. METHODS We conducted two multicenter, randomized, double-blind, placebo-controlled trials of subcutaneous implants containing 16 mg of afamelanotide. Patients in the European Union (74 patients) and the United States (94 patients) were randomly assigned, in a 1:1 ratio, to receive a subcutaneous implant containing either afamelanotide or placebo every 60 days (a total of five implants in the European Union study and three in the U.S study). The type and duration of sun exposure, number and severity of phototoxic reactions, and adverse events were recorded over the respective 180-day and 270-day study periods. Quality of life was assessed with the use of validated questionnaires. A subgroup of U.S. patients underwent photoprovocation testing. The primary efficacy end point was the number of hours of direct exposure to sunlight without pain. RESULTS In the U.S. study, the duration of pain-free time after 6 months was longer in the afamelanotide group (median, 69.4 hours, vs. 40.8 hours in the placebo group; P = 0.04). In the European Union study, the duration of pain-free time after 9 months was also longer in the afamelanotide group than in the placebo group (median, 6.0 hours vs. 0.8 hours; P = 0.005), and the number of phototoxic reactions was lower in the the afamelanotide group (77 vs. 146, P = 0.04). In both trials, quality of life improved with afamelanotide therapy. Adverse events were mostly mild; serious adverse events were not thought to be related to the study drug. CONCLUSIONS Afamelanotide had an acceptable side-effect and adverse-event profile and was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.

UR - http://www.scopus.com/inward/record.url?scp=84936097812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936097812&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1411481

DO - 10.1056/NEJMoa1411481

M3 - Article

C2 - 26132941

AN - SCOPUS:84936097812

VL - 373

SP - 48

EP - 59

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 1

ER -